MAHA vs. the FDA: Dredging up old anti-regulation revisionist history
Science Based Medicine
Last updated: May 4, 2026
The Drug Amendments of 1962, also known as the Kefauver-Harris Amendment, significantly altered drug regulation in the United States. Driven by the thalidomide tragedy, the amendment mandated that drug manufacturers prove both the safety and efficacy of their products before they could be approved for marketing. This shifted the focus from mere safety to a comprehensive assessment of a drug's actual therapeutic benefit.
- The Kefauver-Harris Amendment was a landmark piece of legislation that strengthened the Food and Drug Administration's (FDA) oversight of pharmaceuticals. Prior to this amendment, the primary requirement for drug approval was simply that a drug be safe for its intended use. The thalidomide disaster, where a sedative prescribed to pregnant women caused severe birth defects, highlighted a critical deficiency in this system. The 1962 amendments rectified this by introducing the requirement for manufacturers to demonstrate substantial evidence of a drug's effectiveness for its proposed uses. This included requiring well-controlled clinical trials as proof. The act also introduced stricter regulations for advertising and promotion of prescription drugs, mandating that advertisements present a fair balance of benefits and risks. Furthermore, it established guidelines for the reporting of adverse drug reactions, enhancing post-market surveillance and patient safety. The impact was a more rigorous and scientifically grounded drug approval process, prioritizing public health and ensuring that marketed drugs provided a genuine therapeutic advantage.
